Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis.
Burles A Johnson IiiBenjamin A TeplyCatherine KagemannBridget McGuireKara LombardoYuezhou JingWilliam LangboJonathan I EpsteinGeorge J NettoAlex S BarasAndres MatosoDavid J McConkeyAmol GuptaNita AhujaAshley E RossPhillip M PierorazioEva ComperatJean Hoffman-CensitsNirmish SinglaSunil H PatelMax KatesWoonyoung ChoiTrinity J BivalacquaNoah M HahnPublished in: Bladder cancer (Amsterdam, Netherlands) (2024)
SBC is a chemosensitive subtype, with ypCR rate similar to urothelial bladder cancer following CGD neoadjuvant therapy. Whole transcriptome tissue analyses demonstrate increased expression of immune checkpoint and T-cell genes with therapeutic implications.